Loading
Led SABR-COMET, the trial that showed treating a few metastases with high-dose radiation can prolong survival.
David Palma (London, Ontario) was principal investigator of SABR-COMET, the randomised phase 2 trial showing stereotactic ablative radiotherapy to all sites of oligometastatic disease improves overall survival, which launched the oligometastatic treatment paradigm and the SABR-COMET-3 and -10 phase 3 trials. He also studies treatment de-escalation in head and neck cancer and hosts a widely used teaching channel.
Shares SBRT / SABR (stereotactic radiotherapy) and the tags radiotherapy, sbrt.
Shares SBRT / SABR (stereotactic radiotherapy) and the tags radiotherapy, sbrt.
Shares Stereotactic body radiotherapy (SBRT / SABR), Radiotherapy.
Shares SBRT / SABR (stereotactic radiotherapy) and the tags radiotherapy, sbrt.
Shares Radiotherapy and the tag radiotherapy.
Shares De-escalation, escalation and response-adapted therapy, Radiotherapy.
Shares SBRT / SABR (stereotactic radiotherapy) and the tag radiotherapy.
Shares SBRT / SABR (stereotactic radiotherapy) and the tag radiotherapy.